PUBLICATION
A Zebrafish Heart Failure Model for Assessing Therapeutic Agents
- Authors
- Zhu, X.Y., Wu, S.Q., Guo, S.Y., Yang, H., Xia, B., Li, P., Li, C.Q.
- ID
- ZDB-PUB-180418-35
- Date
- 2018
- Source
- Zebrafish 15(3): 243-253 (Journal)
- Registered Authors
- Keywords
- cardiovascular diseases, heart failure, verapamil, zebrafish
- MeSH Terms
-
- Animals
- Cardiovascular Agents/adverse effects*
- Disease Models, Animal*
- Drug Delivery Systems
- Drug Evaluation, Preclinical/methods*
- Heart Failure/drug therapy*
- Larva/drug effects
- Larva/growth & development
- Zebrafish/growth & development*
- Zebrafish/physiology
- PubMed
- 29653073 Full text @ Zebrafish
Citation
Zhu, X.Y., Wu, S.Q., Guo, S.Y., Yang, H., Xia, B., Li, P., Li, C.Q. (2018) A Zebrafish Heart Failure Model for Assessing Therapeutic Agents. Zebrafish. 15(3):243-253.
Abstract
Heart failure is a leading cause of death and the development of effective and safe therapeutic agents for heart failure has been proven challenging. In this study, taking advantage of larval zebrafish, we developed a zebrafish heart failure model for drug screening and efficacy assessment. Zebrafish at 2 dpf (days postfertilization) were treated with verapamil at a concentration of 200 μM for 30 min, which were determined as optimum conditions for model development. Tested drugs were administered into zebrafish either by direct soaking or circulation microinjection. After treatment, zebrafish were randomly selected and subjected to either visual observation and image acquisition or record videos under a Zebralab Blood Flow System. The therapeutic effects of drugs on zebrafish heart failure were quantified by calculating the efficiency of heart dilatation, venous congestion, cardiac output, and blood flow dynamics. All 8 human heart failure therapeutic drugs (LCZ696, digoxin, irbesartan, metoprolol, qiliqiangxin capsule, enalapril, shenmai injection, and hydrochlorothiazide) showed significant preventive and therapeutic effects on zebrafish heart failure (p < 0.05, p < 0.01, and p < 0.001) in the zebrafish model. The larval zebrafish heart failure model developed and validated in this study could be used for in vivo heart failure studies and for rapid screening and efficacy assessment of preventive and therapeutic drugs.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping